- Current report filing (8-K)
March 20 2012 - 7:41AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
Date of Report (Date of Earliest event Reported): March 20, 2012
CHINA BIOLOGIC PRODUCTS,
INC.
(Exact name of registrant as specified in its
charter)
Delaware
|
001-34566
|
75-2308816
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File No.)
|
(IRS Employer ID No.)
|
18th Floor, Jialong International Building,
19 Chaoyang
Park Road
Chaoyang District, Beijing 100125
Peoples Republic of China
(Address of Principal Executive Offices)
(+86) 10-6598-3111
Registrant's telephone number,
including area code
____________________________________________________________
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (
see
General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS;
ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY
ARRANGEMENTS OF CERTAIN OFFICERS.
On March 19, 2012, China Biologic Products, Inc. (the
Company) received a written consent (the Written Consent) signed by two
shareholders who beneficially own 5,392,624 shares of common stock of the
Company. The Written Consent purports to remove Dr. Tong Jun Lin from the board
of
directors of the Company and appoint Mr. Joseph Chow to
fill the vacancy created by such removal. The Company believes that the number
of shares owned by the shareholders who delivered the Written Consent does not
constitute a sufficient number of shares to effectuate the purported action by
the Written Consent. According to Amendment No. 4 to Schedule 13D filed by Lin
Ling Li, a shareholder of the Company, dated March 19, 2012, Ms. Li delivered a
written request to certain other stockholders of the Company soliciting their
signature to the Written Consent in an attempt that stockholders owning at least
a majority of the outstanding capital stock of the Company would sign the
Written Consent. As of the date hereof, the Company has not received a Written
Consent signed by shareholders owning enough shares to effectuate the action
purported thereby.
After the Company received the Written
Consent signed by the two shareholders, the board of directors of the Company
held a special board meeting on March 19, 2012, at which Dr. Tong Jun Lin
resigned as a director of the Company, a member of the Audit Committee, the
Compensation Committee, and the Governance and Nominating Committee, and as
Chairman of the Governance and Nominating Committee, effective immediately. Dr.
Lin stated that his resignation was due to personal reasons and not because of
any disagreement with the Company on any matter relating to the Companys
operations, policies, or practices.
On the same date, the Companys board of directors appointed
Dr. Yungang Lu, as an independent director of the Company, a member of the Audit
Committee, the Compensation Committee, and the Governance and Nominating
Committee, and as the Chairman of the Governance and Nominating Committee,
effective immediately, to fill the vacancies resulted from Dr. Lins
resignation.
Dr. Lu has served as Managing Director of Seres Asset
Management Limited, an investment manager based in Hong Kong, since August 2009.
Dr. Lu also serves as a board director of the following listed companies:
AsiaInfo-Linkage, Inc., a provider of software solutions and IT services in
Chinas telecommunications industry, China Techfaith Wireless Communication
Technology Ltd., a handheld device company in China, and China Cord Blood
Corporation, a provider of cord blood storage services in China.
From 2004 to July 2009, Dr. Lu was a Managing Director of APAC
Capital Advisors Limited, a Hong Kong-based investment manager specializing in
Greater China equities. Dr. Lu was a research analyst with Credit Suisse First
Boston (Hong Kong), a financial services company, from 1998 to 2004, where his
last position was the head of China Research. Before moving to Credit Suisse, he
worked as an equity analyst focused on regional infrastructure at JP Morgan
Securities Asia, a financial services company, in Hong Kong. Dr. Lu received a
B.S. in Biology from Beijing University, an M.S. in Biochemistry from Brigham
Young University and a Ph.D. in Finance from the University of California, Los
Angeles.
There is no family relationship exists between Dr. Lu and any
directors or executive officers of the Company. In addition, there has been no
transaction, nor is there any currently proposed
transaction between Dr. Lu and the Company that would require disclosure under Item 404(a) of
Regulation S-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 20, 2012
|
CHINA BIOLOGIC PRODUCTS, INC.
|
|
|
|
By:
/s/ Chao Ming Zhao
Chao Ming Zhao
Chief Executive Officer
|
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jul 2023 to Jul 2024